Participant flow

Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants · Source last updated 2024-02-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Defactinib 400 mg BID for 12 Days

   id

   FG000

   title

   Cohort 1 VS-6063 (Defactinib)

2. description

   Defactinib 400 mg BID for 35 Days

   id

   FG001

   title

   Cohort 2

3. description

   Defactinib 400 mg BID for 21 Days

   id

   FG002

   title

   Cohort 3

4. description

   Defactinib 100 mg BID for 21 Days

   id

   FG003

   title

   Cohort 4

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         10

      2. group Id

         FG001

         num Subjects

         10

      3. group Id

         FG002

         num Subjects

         10

      4. group Id

         FG003

         num Subjects

         5

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         10

      2. group Id

         FG001

         num Subjects

         10

      3. group Id

         FG002

         num Subjects

         10

      4. group Id

         FG003

         num Subjects

         5

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         0

      4. group Id

         FG003

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice